Comparison of Disability and Quality of Life in Parkinsonian Syndromes (P06.067)

Abstract

Objective: To compare the levels of quality of life (QoL), disability and cognitive/motor impairment among 5 parkinsonian disorders: Corticobasal Syndrome (CBS), Lewy Body Dementia (DLB), Multisystem Atrophy (MSA), Parkinson9s Disease (PD) and Progressive Supranuclear Palsy (PSP). Background Parkinsonian syndromes manifest different degrees of motor symptoms, cognitive dysfunction and psychiatric co-morbidity, and variable response to antiparkinsonian drugs. These variations are likely to result in different levels of impairment, disability and QoL. Design/Methods: Patients from 5 diagnostic groups [PD(N=1202), PSP(N=39), MSA(N=32), DLB(N= 23), CBS(N=20)] were assessed for parkinsonism (Total UPDRS), cognitive impairment (MMSE), Health-related QoL (SF-12 Health Status Survey) and disability (OARS ADL scale). Groups were compared using ANOVA/ANCOVA models providing a global F-test, and post-hoc pairwise comparisons using t-tests. Results: PD patients were youngest (65.8(11)yrs) with longest disease duration (5.7(5.7)yrs; p=.001). CBS and DLB patients were oldest (72.7(6.6) and 72.5(9.3); p Conclusions: DLB and MSA were associated with the greatest severity of impairment, disability, and QoL amongst 5 parkinsonian syndromes. PD is associated with less morbidity despite longer disease duration. These results suggest that the severe impact of DLB is related to the combination of cognitive, psychiatric and motor impairments, and the severe impact of MSA is related to greater parkinsonian symptoms. This study underscores the need for effective interventions for atypical parkinsonian syndromes. Supported by: The Rosalyn Newman Foundation. Disclosure: Dr. Figari-Jordan has nothing to disclose. Dr. Gruber-Baldini has nothing to disclose. Dr. Anderson has received personal compensation for activities with Boehringer Ingelheim R11 as a consultant and medical evaluator. Dr. Anderson has received personal compensation in an editorial capacity for Current Treatment Options in Neurology. Dr. Reich has received (royalty or license fee or contractual rights) payments from Informa Publishers. Dr. Weiner has received personal compensation from Santhera and Rexahn. Dr. Weiner has received personal compensation in an editorial capacity for Neurological Reviews and Current Treatment Options in Neurology. Dr. Weiner has recieved research support from Teva Neuroscience, Boehringer Ingelheim Pharmaceuticals, Inc., and EMD Serono. Dr. Fishman has received personal compensation for activities with Pfizer Inc, Forest Laboratories, Inc., Ortho-McNeil Pharmaceuticals, Inc., GlaxoSmithKline, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Novartis, and Allergan, Inc., as a speaker. Dr. Fishman has received personal compensation in an editorial capacity for Neura. Dr. Shulman has nothing to disclose.